Journal of Infectious Diseases

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections

December 27, 2012 By Matt Feldman In Press Releases No Comments

Read the new paper published in Journal of Infectious Diseases.

Abstract

We established a new field clone of Plasmodium falciparum for use in controlled human malaria infections and vaccine studies to complement the current small portfolio of P. falciparum strains, primarily based on NF54. The Cambodian clone NF135.C10 consistently produced gametocytes and generated substantial numbers of sporozoites in Anopheles mosquitoes and diverged from NF54 parasites by genetic markers. In a controlled human malaria infection trial, 3 of 5 volunteers challenged by mosquitoes infected with NF135.C10 and 4 of 5 challenged with NF54 developed parasitemia as detected with microscopy. The |

The Potential Role of Vaccines in the Elimination of Falciparum Malaria and the Eventual Eradication of Malaria

December 1, 2009 By Matt Feldman In Publications No Comments

Read the full article in the Journal of Infectious Diseases.

There has been a recent call for global malaria eradication. The prospects of achieving this ambitious goal are diminished by the limited tool set now available—notably, the lack of a licensed malaria vaccine. This is in large part because the multistage Plasmodium parasites that cause malaria have a much more complex life cycle and larger genomes than do the viruses that cause smallpox and polio, the only infectious agents that have been completely or nearly eradicated from the world by vaccines. We think that (1) vaccines could play as |

Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites

April 1, 2002 By Matt Feldman In Publications No Comments

During 1989-1999, 11 volunteers were immunized by the bites of 1001-2927 irradiated mosquitoes harboring infectious sporozoites of Plasmodium falciparum (Pf) strain NF54 or clone 3D7/NF54. Ten volunteers were first challenged by the bites of Pf-infected mosquitoes 2-9 weeks after the last immunization, and all were protected. A volunteer challenged 10 weeks after the last immunization was not protected. Five previously protected volunteers were rechallenged 23-42 weeks after a secondary immunization, and 4 were protected.